Future of HIV2 and HIV2 +  1 Infected Patients Treated with Antiretrovirals Followed at the Day Hospital HIV Care Unit from 2011 to 2015. (December 2022)

• Record Type: Journal Article
• Authors: Diallo, Ismaël; Ouédraogo, Smaïla; Sawadogo, Abdoulaye; Ouédraogo, Gafourou Arsène; Diendéré, Eric Arnaud; Zoungrana, Jacques; Sondo, Apoline Kongnimissom; Bognounou, Réné; Savadogo, Mamoudou; Poda, Armel; Drabo, Youssouf Joseph
• Is Part Of: Journal of the International Association of Providers of AIDS Care. Volume 21(2022)
• Publication Date: 2022-12
• Subjects: Future -- HIV2 -- HIV2 + 1 -- Burkina Faso; AIDS (Disease) -- Periodicals; 616.9792
• DOI: 10.1177/23259582221143675
• Languages: English
• ISSNs: 2325-9574

Abstract

Introduction: HIV2 is endemic in West Africa. In Burkina Faso, its prevalence was estimated at 2%. The aim of this work was to evaluate the follow-up of patients and also to contribute to the availability of data.Methods: We involved 18 years or older. Infection was screened according to the national algorithm. A cross- sectional study from first June 2017 to 31 December 2017 was performed. For each patient, sociodemographic, clinical, biological, therapeutic and evolution data were collected and analyzed.Results: The proportion of patients infected with HIV2 (n = 48; 1.7%) and HIV2 + 1 (n = 67; 2.4%) was 4.3%. The sex rat mean age was 50.3 ± 8.5 years. The combination of 2INTI + LPV/r was the most prescribed (n = 73; 63.5%). The average gain of LTCD4 has evolved from + 236 cells/mm 3 in 2011 to + 364 cells/mm 3 in 2015. The retention rate at grade 5 was about 70%.Conclusion: The immunological and clinic response of the patients was satisfactory. More than half of the patients remained in the continuum of care after five years of follow-up.